



## Board of Directors

### **Michael F. Bigham**

*Director*

*Abingworth Management Limited*

Mr. Bigham has served as a member of Dynogen's Board of Directors since April 2004. Mr. Bigham has been a Director at Abingworth Management Limited, a venture capital firm, since December 2002. From 2000 to 2004, Mr. Bigham served as Vice Chairman of Corixa Corporation, a publicly-traded biotechnology company. From 1996 to 2000, Mr. Bigham was President and Chief Executive Officer of Coulter Pharmaceuticals, until it merged with Corixa. Prior to Coulter, Mr. Bigham served in executive management from 1988 to 1996 at Gilead Sciences, Inc., a publicly-traded biopharmaceutical company, most recently as Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead, Mr. Bigham was a Co-Head of Healthcare Investment Banking at Hambrecht & Quist from 1984 to 1988. Mr. Bigham currently serves on the Boards of Xenogen Corporation, as well as several private companies. Mr. Bigham earned his bachelor's degree with distinction from the University of Virginia and qualified as a Certified Public Accountant before receiving his Master of Business Administration at the Stanford University Graduate School of Business.

### **Kate E. Bingham**

*Managing Partner*

*SV Life Sciences*

Ms. Bingham has served as a member of Dynogen's Board of Directors since April 2004. Ms. Bingham is Managing Partner with SV Life Sciences, and has been with the venture capital firm since 1991. Prior to joining SV Life Sciences, Ms. Bingham worked in business development for Vertex Pharmaceuticals from 1990 to 1991, and at Monitor Company, a strategy consulting firm, from 1987 to 1989. Ms. Bingham has a Master's degree in biochemistry from Oxford University and was a Baker Scholar at Harvard Business School where she received a Master of Business Administration.

### **Lee R. Brettman, M.D., FACP**

*President, CEO and Director*

Dr. Brettman has served as Dynogen's President and Chief Executive Officer and as a member of the Board of Directors since the Company's founding in March 2002. From 2001 to 2003, Dr. Brettman was an Entrepreneur-in-Residence at Oxford Bioscience Partners, a life science venture capital firm. From 1998 to 2001, Dr. Brettman was Chief Medical Officer and Senior Vice President of Medical and Regulatory Affairs at Millennium Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. From 1995 to 1999, Dr. Brettman served as Chief Medical Officer and Senior Vice President at LeukoSite Inc., a biopharmaceutical company, before it merged with Millennium. Prior to joining LeukoSite, Dr. Brettman worked in the industry as a Senior Director, Clinical Research at biopharmaceutical company

Vertex Pharmaceuticals, Inc. from 1993 to 1995, Director of Anti-Infectives Research at the Schering Plough Research Institute from 1992 to 1993, and Associate Director of the Anti-Infectives group at the Robert Wood Johnson Pharmaceutical Research Institute from 1990 to 1992. Dr. Brettman received dual bachelor's degrees in biology and Russian literature from the Massachusetts Institute of Technology and his M.D. from the Baylor College of Medicine. Dr. Brettman is Board certified in internal medicine and infectious diseases and is a Fellow of the American College of Physicians and the Infectious Diseases Society of America.

**Mark P. Carthy**

*General Partner*

*Oxford Bioscience Partners*

Mr. Carthy has served a member of Dynogen's Board of Directors since January 2006. Mr. Carthy has been a General Partner at Oxford Bioscience Partners since October 2000. From 1998 to 2000, Mr. Carthy was Biotechnology Portfolio Manager at Morningside Ventures, a venture capital firm. Prior to joining Morningside, Mr. Carthy was Chief Business Officer at Cubist Pharmaceuticals Inc, a publicly-traded biopharmaceutical company, from 1997 to 1998, and a Senior Director of Business Development at Vertex Pharmaceuticals from 1992 to 1997. Mr. Carthy currently serves on the Boards of Cyberkinetics Neurotechnology Systems, Inc. as well as several private companies. Mr. Carthy received his bachelor's degree in chemical engineering from University College Dublin, a Master of Science in chemical engineering from the University of Missouri, and a Master of Business Administration from Harvard Business School.

**Augustine J. Lawlor**

*General Partner*

*HealthCare Ventures, LLC*

Mr. Lawlor has served as a member of the Board of Directors since March 2002. Mr. Lawlor is General Partner at HealthCare Ventures, LLC, a venture capital firm, and has been with the firm since 2000. From 1997 to 2000, Mr. Lawlor was Chief Operating Officer at LeukoSite. Before LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development at Alpha-Beta Technology, Inc. a publicly-traded biopharmaceutical company. Prior to Alpha-Beta Technology, Mr. Lawlor held similar positions in industry at BioSurface Technology and Armstrong Pharmaceuticals. Mr. Lawlor began his career as a management consultant with accounting firm KPMG Peat Marwick. Mr. Lawlor currently serves on the Boards of Human Genome Sciences, Inc., Replidyne, Inc. and several private companies. Mr. Lawlor received his bachelor's degree from the University of New Hampshire, where he was elected to Phi Beta Kappa, and a Master's degree in management from Yale University.